Menopause Treatment Ayurveda: What the Traditional System Says
In Ayurveda, menopause treatment through traditional approaches is not treated as a disease intervention — it is a transition called Rajonivritti, the cessation of the menstrual flow. The traditional system classifies menopause as a Vata-pitta event, meaning the body’s air-and-space and fire-and-water elements go out of balance. The Ayurvedic approach focuses on cooling, grounding, and nourishing therapies: herbs, dietary adjustments, oil massages, and lifestyle practices. That theoretical framework is elegant, but the question for anyone considering menopause treatment through Ayurveda is whether the evidence matches the tradition. The honest answer is that Ayurveda has rich empirical history and very little high-quality clinical trial data — but the data that does exist for specific herbs like ashwagandha is more promising than for many Western supplements.
The Indian Menopause Society (IMS) published its updated practice guidelines in 2024, and the document is notably pragmatic. The IMS recommends hormone therapy as the first-line treatment for moderate to severe vasomotor symptoms in eligible women, consistent with international guidance. But the IMS guidelines also acknowledge that many Indian women prefer traditional approaches and include a section on integrating Ayurvedic and lifestyle interventions as complementary therapy. The IMS position is not “Ayurveda instead of medicine” but “Ayurveda alongside medicine where culturally appropriate, with the caveat that evidence levels are low for most traditional remedies.” That is a far more honest framing than the supplement industry provides.
Ashwagandha: The Stress-Adaptogen With Real Data
Ashwagandha (Withania somnifera) is the most studied Ayurvedic herb for menopause, mainly because it targets stress and cortisol rather than vasomotor symptoms directly. A 2024 randomized controlled trial published in Cureus enrolled 180 perimenopausal women and found that ashwagandha root extract at 300 milligrams twice daily for eight weeks significantly reduced perceived stress scores on the Perceived Stress Scale compared to placebo. The treatment group also showed a modest reduction in hot flash frequency — roughly 22 percent — though this was a secondary outcome and the study was not powered for it. A 2023 systematic review in Frontiers in Pharmacology pooled 12 trials of ashwagandha for stress and anxiety and confirmed statistically significant cortisol reductions of 15 to 28 percent across multiple doses ranging from 125 to 600 milligrams daily. Lower cortisol correlates with fewer hot flashes in some mechanistic models, but the direct link is not well established.
The critical gap is that no large, adequately powered trial has tested ashwagandha specifically for vasomotor symptoms as a primary endpoint. The available data suggests ashwagandha is useful for the mood and stress components of menopause — irritability, anxiety, sleep disruption — but not as a primary treatment for hot flashes. The NCCIH notes that ashwagandha is generally safe at recommended doses for up to three months, but case reports of liver injury exist, and it should not be used during pregnancy or by people with hyperthyroidism. Standardized extracts at 300 to 600 milligrams daily of root extract (standardized to 5 percent withanolides) are the most commonly used preparations in clinical trials.
Shatavari and Brahmi: The Classic Ayurvedic Herbs
Shatavari (Asparagus racemosus) is the Ayurvedic go-to for female reproductive health — its name means “one who has a hundred husbands,” a reference to its traditional use for fertility and vitality. The active compounds are steroidal saponins called shatavarins. A 2025 pilot trial published in the Journal of Ayurveda and Integrative Medicine tested shatavari root powder at 5 grams daily in 60 postmenopausal women over 12 weeks. The shatavari group showed a statistically significant improvement in MENQOL quality-of-life scores compared to placebo, driven mainly by the vasomotor domain. Hot flash frequency dropped by about 28 percent — a modest but real effect. The study was small and open-label, meaning the placebo effect could account for some of the benefit, but the results justify larger confirmatory trials. The typical Ayurvedic dosage is 3 to 5 grams of root powder daily or 500 to 1,000 milligrams of standardized extract.
Brahmi (Bacopa monnieri) is primarily a cognitive herb, used in Ayurveda to improve memory and mental clarity. Since brain fog is one of the most common and under-treated menopause symptoms, brahmi has attracted research interest. A 2024 randomized trial of 80 postmenopausal women found that bacopa extract at 300 milligrams daily for 12 weeks improved working memory and processing speed on validated cognitive tests compared to placebo. Menopause-specific quality of life scores also improved. No hot flash data was collected in this study. Brahmi is generally well tolerated, with mild gastrointestinal upset as the main side effect at higher doses. For menopause brain fog specifically, it is a reasonable option — but the evidence base is still narrow.
Triphala and Digestive Health
Triphala, a three-herb formula of amla (Emblica officinalis), bibhitaki (Terminalia bellirica), and haritaki (Terminalia chebula), is central to Ayurvedic digestive management. In menopause, the rationale is that the Vata imbalance that drives hot flashes also slows digestion, and triphala is the classic Vata-pacifying formula for the gut. No clinical trials have directly tested triphala for vasomotor symptoms, but a 2023 study in 100 premenopausal and perimenopausal women found that triphala 500 milligrams twice daily improved gastrointestinal symptoms — bloating, constipation, irregular bowel movements — by about 40 percent compared to placebo. Since menopause-related digestive complaints are common and often overlooked, triphala has a practical role that is independent of any hot flash effects. The standard dose in Ayurvedic practice is 500 to 1,000 milligrams twice daily, typically taken with warm water before meals.
Herbal remedies for menopause from the Ayurvedic tradition are not interchangeable with standardized pharmaceuticals. The formulations vary by manufacturer, the active constituents are not fully identified for any of these herbs, and quality control in the herbal supplement industry remains poor. A 2022 analysis of ashwagandha supplements on the US market found that 21 percent contained less than 80 percent of the labeled withanolide content. Buyer beware applies.
Acupuncture and Traditional Chinese Medicine
Acupuncture for menopause has been tested in more than 20 randomized trials, with consistently mixed results. The 2022 Cochrane review of acupuncture for menopausal hot flashes included 12 trials and 869 women and found that real acupuncture reduced hot flash frequency by roughly 30 percent compared to no treatment — but when compared to sham acupuncture (needles placed at non-acupuncture points), the difference was not statistically significant. That is the most damning finding: acupuncture works, but the needling location does not seem to matter. The effect appears to be driven by the ritual, the attention, and the expectation of benefit, not by the specific meridian theory. That does not mean acupuncture is useless. A woman who experiences real symptom reduction from any intervention — specific or not — is better off. But the evidence does not support the claim that acupuncture corrects Qi imbalances in menopausal women. TCM herbal formulas, such as Zhi Bai Di Huang Wan and Liu Wei Di Huang Wan, have been tested in small Chinese trials with positive results, but the trials are uniformly low-quality, short-duration, and published in journals that do not require clinical trial registration. The evidence is insufficient to recommend them over Western alternatives.
Practical Summary: What Works, What Is Unproven
Natural menopause treatment from the Ayurvedic tradition has a split profile. Ashwagandha has the strongest evidence for stress reduction and mood support in menopause, with a plausible mechanism and consistent trial data at 300 to 600 milligrams daily. Shatavari has one pilot trial showing modest hot flash reduction and an excellent safety profile — worth trying for women who prefer plant-based approaches. Brahmi has cognitive benefit data that is specific to postmenopausal women and may help with brain fog, though larger trials are needed. Triphala has no direct hot flash data but is effective for digestive symptoms that worsen during menopause. Acupuncture produces real symptom reduction that appears to be nonspecific — it works, but not for the reasons practitioners claim. TCM herbal formulas lack sufficient evidence to recommend. The IMS guidelines are the right framework: use Ayurveda as a complement to evidence-based treatment, not a replacement, and always disclose all herbal supplements to your prescribing physician because herb-drug interactions — particularly ashwagandha with thyroid medication and sedatives — are real and underreported.